Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seattle Genetics Will Test Oncology Pricing Acceptance With Adcetris

Executive Summary

Now that Seattle Genetics Inc. is making the transition into a commercial drug company with the FDA approval of its oncologic Adcetris, its success will depend on how effectively it can convince payers, patients and physicians that Adcetris is worth its premium price and how well it can extend the drug’s reach to larger patient markets.
Advertisement

Related Content

Deal Watch: Seattle Genetics And Genmab Partner Again On Anti-Cancer ADC
Sell The Launch: Going Commercial, Some Biotechs Are Left Hanging
Pfizer’s Xalkori Joins The Six-Figure Oncology Drug Club
Deals Of The Week: Baxter/Baxa, Par Pharmaceuticals/Anchen, Sanofi/Universal Medicare
Seattle Genetics Commits To Simultaneous Confirmatory Trials For Adcetris
Disappointing Provenge Sales Stir Doubts About Demand
Seattle Genetics Hoping Its Adcetris Trials Can Do Double Duty
Roche's T-DM1 Early Filing Strategy Backfires As FDA Refuses To File BLA
Roche's T-DM1 Early Filing Strategy Backfires As FDA Refuses To File BLA
Takeda Partners With Seattle Genetics On Lymphoma Candidate In Pivotal Trials

Topics

Advertisement
UsernamePublicRestriction

Register

PS053723

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel